SUBSTITUTED GUANIDINES HAVING HIGH BINDING TO THE SIGMA RECEPTOR AND THE USE THEREOF
申请人:STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of
公开号:EP0532642A1
公开(公告)日:1993-03-24
EP0532642A4
申请人:——
公开号:EP0532642A4
公开(公告)日:1994-04-27
US5574070A
申请人:——
公开号:US5574070A
公开(公告)日:1996-11-12
[EN] SUBSTITUTED GUANIDINES HAVING HIGH BINDING TO THE SIGMA RECEPTOR AND THE USE THEREOF
申请人:STATE OF OREGON, acting by and through the OREGON STATE BOARD OF HIGHER EDUCATION, acting for and onbehalf of the OREGON HEALTH SCIENCES UNIVERSITY
公开号:WO1991018868A1
公开(公告)日:1991-12-12
(EN) The invention relates to a method for the treatment or prophylaxis of psychosis, depression, hypertension, or anxiety in an animal by administering an effective amount of an N,N'-disubstituted guanidine or 2-imino-imidazolidine having a high affinity for the sigma receptor. The invention also relates to the novel guanidines of the invention as well as pharmaceutical compositions thereof.(FR) Procédé servant au traitement et à la prophylaxie de la psychose, de la dépression, de l'hypertension et de l'angoisse chez un animal au moyen de l'administration d'une quantité efficace de guanidine N,N'-disubstituée ou de 2-imino-imidazolidine ayant un coefficient d'affinité élevé avec le récepteur sigma. On décrit aussi de nouvelles guanidines ainsi que des compositions pharmaceutiques les contenant.
Synthesis and structure-activity relationships of N,N'-di-o-tolylguanidine analogs, high-affinity ligands for the haloperidol-sensitive .sigma. receptor
作者:Michael W. Scherz、Michelle Fialeix、James B. Fischer、N. Laxma Reddy、Alfred C. Server、Mark S. Sonders、Barbara C. Tester、Eckard Weber、Scott T. Wong、John F. W. Keana
DOI:10.1021/jm00171a016
日期:1990.9
2-CH3C6H5). Replacement of one or both aryl rings with certain saturated carbocycles (e.g. cyclohexyl, norbornyl, or adamantyl) leads to a significant increase in affinity. By combining the best aromatic and best saturated carbocyclic substituents in the same molecule, we arrived at some of the most potent sigma ligands described to date (e.g. N-exo-2-norbornyl-N'-(2-iodophenyl)guanidine, IC50 = 3 nM vs [3H]-3)
着眼于新型非典型抗精神病药的开发,我们研究了氟哌啶醇敏感的sigma受体的N,N'-二-邻甲苯基胍(DTG,3)及其同类物的结构亲和力关系。合成了许多DTG类似物,并在豚鼠脑膜匀浆的体外放射性配体置换实验中使用了高sigma特异性放射性配体[3H] -3和[3H]-(+)-3-(3-羟苯基)进行了评估。 -N-(1-丙基)哌啶和苯环利定(PCP)受体特异性化合物[3H] -N- [1-(2-噻吩基)-环己基]哌啶和[3H]-(+)-5-甲基-10 ,11-二氢-5H-二苯并[a,d]环庚烯-5,10-亚胺。N,N'-二芳基胍对sigma受体的亲和力随邻位取代基的体积比C2H5大而增加。疏水取代基通常优于类似位置的亲水取代基。此外,电子中性取代基优于强电子给体或吸电子基团。只要胍的至少一侧带有优选基团(例如2-CH 3 C 6 H 5),通常就可以保持与σ受体的显着结合。用某些饱和的碳环(例